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CLINICAL RESEARCH

Randomized Controlled Trial
of Subcutaneous Epoetin Alfa-epbx
Versus Epoetin Alfa in End-Stage
Kidney Disease
Steven Fishbane1, Bruce S. Spinowitz2, Wayne A. Wisemandle3 and Nancy E. Martin3
1
Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA; 2Division of
Nephrology, New York Presbyterian Queens, Flushing, New York, USA; and 3Global Clinical Development, Hospira, Inc,
a Pﬁzer company, Lake Forest, Illinois, USA

Introduction: This double-blind, randomized controlled trial compared the safety and efﬁcacy of subcutaneous epoetin alfa-epbx, an epoetin alfa biosimilar, with the reference product, epoetin alfa, in hemodialysis patients with end-stage kidney disease (ESKD) and anemia who were receiving epoetin alfa
maintenance treatment.
Methods: Eligible patients (n ¼ 320) were randomized (1:1) to subcutaneous epoetin alfa-epbx or epoetin
alfa in a titration phase; patients who demonstrated stable subcutaneous dosing (n ¼ 246) were rerandomized to receive subcutaneous epoetin alfa-epbx or epoetin alfa 1 to 3 times per week in a
16-week maintenance phase. Co-primary endpoints were least-squares mean difference between treatments in mean weekly hemoglobin concentration and mean weekly epoetin dose per kilogram body
weight (BW) during the last 4 weeks of treatment in the maintenance phase.
Results: The least-squares mean difference (95% conﬁdence interval [CI]) between treatments in weekly
hemoglobin was 0.04 g/dl (0.17 to 0.24 g/dl) and weekly epoetin dose/kg BW was 2.34 U/kg per week
(14.51 to 9.82 U/kg per week). The 95% CIs were contained within the prespeciﬁed equivalence margins
of 0.5 g/dl (weekly hemoglobin) and 45 U/kg per week (weekly epoetin dose/kg BW). In the epoetin alfaepbx and epoetin alfa groups, respectively, 4.0% and 4.1% of patients required blood transfusions, 69.7%
and 70.5% reported adverse events, 18.9% and 27.0% reported serious adverse events, and 3 and 2 deaths
were reported. Five patients were conﬁrmed positive for anti-recombinant human erythropoietin antibody,
2 of whom tested positive at baseline. All patients tested negative for neutralizing antibodies.
Conclusions: This comparative clinical trial demonstrated equivalence in efﬁcacy and similar safety of
subcutaneously administered epoetin alfa-epbx to epoetin alfa.
Kidney Int Rep (2019) 4, 1235–1247; https://doi.org/10.1016/j.ekir.2019.05.010
KEYWORDS: biosimilar; efﬁcacy; end-stage kidney disease; epoetin alfa; subcutaneous administration; safety
ª 2019 Published by Elsevier, Inc., on behalf of the International Society of Nephrology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nemia is a serious and common complication of
chronic kidney disease (CKD), often developing
early in the course of CKD and worsening with disease progression.1,2 Anemia in patients with CKD is
primarily caused by inadequate production of
erythropoietin by damaged kidneys.3 Epoetin alfa
(EPOGEN/PROCRIT; Amgen Inc., Thousand Oaks,
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CA, USA/Janssen Products LP, Horsham, PA, USA)
was the ﬁrst recombinant human erythropoietin
(epoetin) approved by the US Food and Drug
Administration for treatment of anemia in patients
with CKD,4,5 and is one of the most commonly used
erythropoiesis-stimulating agents (ESAs) among hemodialysis patients in the United States.6 Subcutaneous (s.c.) or i.v. administration of epoetin in
patients with CKD and anemia results in clinically
signiﬁcant increases in hemoglobin, reduces the
need for transfusion, and demonstrates efﬁcacy
in both corrective and maintenance treatment.7–9
However, costs of ESAs are signiﬁcant. For
example, in 2016, costs of ESAs for Medicare-certiﬁed
dialysis facilities for patients with ESKD exceeded
1235
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$1.7 billion (estimate provided by Mark Stephens,
personal communication, August 2, 2018, based
on an analysis of Centers for Medicare & Medicaid
Services, Renal Cost Reports, 2018, available at:
https://www.cms.gov/Research-Statistics-Data-andSystems/Downloadable-Public-Use-Files/Cost-Reports/
RNL-2011-form.html).
Biosimilars are biologic drugs that are highly similar to a
licensed (i.e., originator or reference) biologic product.10,11
Speciﬁc guidance for biosimilar approval was ﬁrst developed by the European Medicines Agency in 2005,10 and
multiple approved biosimilar epoetin products have been
in use in Europe since 2007.12–16 In the United States, the
Food and Drug Administration developed a regulatory
framework for biosimilar approval following passage of the
Biologics Price Competition and Innovation Act of 2009,
which created an abbreviated licensure pathway for biosimilars.11,17 This prompted development of epoetin biosimilars that may provide additional treatment options and
have the potential to lower the costs of epoetin treatment.18
Epoetin alfa-epbx (RETACRIT; Hospira Inc, a Pﬁzer
company, Lake Forest, IL) is a biosimilar of epoetin
alfa.19 Epoetin alfa-epbx and epoetin alfa are identical in
amino acid sequence and comparable in carbohydrate
composition.20 Epoetin alfa-epbx was approved by the
US Food and Drug Administration in May 2018 for all
indications of epoetin alfa, and can be administered i.v.
or s.c.19 As part of the clinical development program
that supported regulatory approval of epoetin alfa-epbx,
a comparative clinical study demonstrated equivalence
in efﬁcacy and similar safety of epoetin alfa-epbx to
epoetin alfa when administered i.v. to hemodialysis
patients with anemia.21 As part of the same development
program, the current study was conducted to evaluate
the equivalence of epoetin alfa-epbx to epoetin alfa
when administered s.c. to hemodialysis patients with
anemia. This s.c.-administration study was additionally
requested by the US Food and Drug Administration
because the immunogenicity of a protein can be inﬂuenced by the route of administration.22,23 Subcutaneous
administration was selected because it is generally
considered to be the route most likely to elicit an immune reaction,23,24 and was therefore considered a more
sensitive assessment for detecting potential differences
in immunogenicity between epoetin alfa-epbx and
epoetin alfa, should they exist.
METHODS
Patient Population
The study included male and nonpregnant female hemodialysis patients, aged 18 to 80 years, with ESKD and
anemia who, before randomization, were on stable i.v.
or s.c. epoetin alfa 1 to 3 times per week and had stable
1236
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hemoglobin (mean 9.0–11.0 g/dl) for $4 weeks; were
on stable, adequate dialysis for $12 weeks; and had
adequate iron stores (plasma ferritin >100 mg/l, transferrin saturation >20%). Exclusion criteria included
active, uncontrolled systemic inﬂammatory, or malignant
conditions; uncontrolled hypertension; recent myocardial
infarction, stroke, major thrombotic event, seizure, or
decompensated heart failure; required maintenance doses
of epoetin alfa >600 U/kg per week; received long-acting
ESAs within 12 weeks before randomization; or had
recently donated or lost >475 ml of blood.
Study Design
This was a multicenter, randomized, double-blind, activecontrolled, parallel-group efﬁcacy and safety trial
(ClinicalTrials.gov; identiﬁer NCT01473420) conducted in
the United States to evaluate the equivalence of s.c.administered epoetin alfa-epbx to epoetin alfa in hemodialysis patients with ESKD and anemia who were receiving
epoetin alfa maintenance treatment. All patients who
satisﬁed the entry criteria during a 4-week screening
period were randomized (1:1) into a titration phase
(Figure 1). Patients who were on i.v. epoetin alfa during
screening received s.c. epoetin (epoetin alfa-epbx or
epoetin alfa) 1 to 3 times per week in the titration phase;
the starting dose was 20% to 30% lower than the i.v.
epoetin alfa dose received during the last week of
screening. Patients were treated for 12 to 18 weeks in the
titration phase, based on evidence that safe and effective
transition from chronic i.v. to s.c. epoetin alfa requires
approximately 12 weeks, or longer, because of variability
in patient response.25
Patients who demonstrated optimal stable dosing on
s.c. epoetin by the last 4 weeks of the titration phase were
randomized into a 16-week maintenance phase to receive
s.c. study drug 1 to 3 times per week at the optimal dose
demonstrated during the titration phase. Optimal stable
dosing was deﬁned as having met all of the following
requirements during the 4 weeks before randomization
and before entrance into the maintenance phase: a change
in epoetin dosing of no more than 10% from the mean, a
mean hemoglobin of 9.0 to 11.0 g/dl, no more than 1 hemoglobin result outside of range from 9.0 to 11.0 g/dl, and
no hemoglobin result more than 1 g/dl from the mean
hemoglobin level. Conversely, patients who did not
demonstrate optimal stable dosing were excluded from
the maintenance phase and discontinued from study.
Patients who were on s.c. epoetin alfa during screening
received study drug assignment, without undergoing
dose titration, and were immediately re-randomized into
the maintenance phase to receive s.c. epoetin alfa-epbx or
epoetin alfa at the same dose received during screening.
Randomization (1:1) into the maintenance phase was
stratiﬁed by titration-phase drug assignment and dose
Kidney International Reports (2019) 4, 1235–1247
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Epoetin alfa-epbx treatment
Epoetin alfa treatment

Figure 1. Study design. aPatients who were on subcutaneous treatment at the time of screening and demonstrated optimal stable dosing for 4
consecutive weeks were randomized (R) into the titration phase, received study drug assignment, and then proceeded directly to the maintenance phase if they satisfied all other study criteria for entry into the maintenance phase. Patients who did not demonstrate optimal and
stable dosing by week 18 did not continue to the maintenance phase. bPatients who discontinued the study drug early during the maintenance
phase received standard-of-care erythropoiesis-stimulating agent treatment until either the follow-up visit or entry into the long-term safety
study (LTSS). cPatients who did not enter the LTSS underwent a follow-up visit, 4 weeks after the last schedule of study activities. dPatients had
up to 28 days from completion of week 16 of the maintenance phase to enter into the LTSS. ePrimary efficacy endpoints will be assessed during
the last 4 weeks of the maintenance phase.

level (low, medium, or high). This second randomization
into the maintenance phase was intended to evenly
distribute potential bias (resulting from possible carryover effect of variable treatment, study drug dose, allocation, and duration in the titration phase) on the
primary efﬁcacy variables measured for the parallel
treatment groups in the ﬁxed-length maintenance phase.
Re-randomization into the maintenance phase also was
intended to evenly distribute baseline characteristics.
Study drug assignments for each phase were obtained by
site personnel, unblinded with respect to study treatment, via an Interactive Voice Response System/Interactive Web-based Response System.
During the titration and maintenance phases, dosing
for study drugs was individually adjusted, following the
epoetin alfa US prescribing information,26,27 to maintain
hemoglobin within the target range (9.0–11.0 g/dl). Doseadjustment consideration during the maintenance phase
was made at least weekly by the investigator, based on
hemoglobin levels over the previous 4 weeks. Dosing
frequency was at the investigator’s discretion. Patients
who discontinued treatment during the maintenance
phase received short-acting, non–study-drug, standardKidney International Reports (2019) 4, 1235–1247

of-care (SoC) ESAs (epoetin alfa) and completed scheduled study assessments for the remainder of the maintenance phase. All patients who completed the maintenance
phase qualiﬁed for entry into an open-label extension
study under a separate protocol to receive s.c. epoetin
alfa-epbx for up to an additional 48 weeks. Patients not
entering the extension study continued with SoC treatment and had a follow-up assessment 4 weeks after the
end of the maintenance phase (Figure 1).
The study was conducted from January 2012 to
February 2014, in compliance with Institutional Review
Board regulations, the Declaration of Helsinki, the International Conference on Harmonization guidelines, Good
Clinical Practice guidelines, and all applicable regulatory
requirements. Patients provided written informed consent
before the performance of any study-speciﬁc procedures.
Study Drug
Epoetin alfa-epbx (RETACRIT; Hospira Inc) was supplied
as an aqueous, phosphate-buffered, isotonic solution,
containing polysorbate 20. Epoetin alfa (EPOGEN; Amgen
Inc.) was used as the reference epoetin product. All injections were administered at least 30 to 60 minutes
1237
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before the end of dialysis by site personnel who were
blinded with respect to study treatments. To ensure
compliance, study drug was prepared and administrations were recorded by site personnel who were unblinded with respect to study treatment.
Assessments
Hemoglobin levels, epoetin dose/kg BW, concomitant
medications, transfusion requirements, vital signs, postdialysis BW, tolerability, and adverse events (AEs) were
recorded at each weekly visit. Electrocardiograms were
performed at screening, week 16, and follow-up. Clinical
chemistry, hematology, coagulation parameters, and iron
status were assessed at screening, before initial dosing,
and monthly throughout the study. Blood was collected
before the ﬁrst (week 1) and last doses of study drug in
the titration phase, before dosing at weeks 1 and 16 of the
maintenance phase, and at follow-up for assessment of
anti-recombinant human erythropoietin (rhEPO)–binding
antibodies by radioimmunoprecipitation. If positive, the
anti-rhEPO antibody response was quantiﬁed in the
radioimmunoprecipitation assay by titrating the samples.
Antibody titer was reported as the highest dilution that
was equal to or above the titration cut point. Anti-rhEPO
antibody-positive samples were further tested for antirhEPO neutralizing antibodies by cell-based assay, using current validated methods. All AEs were rated by the
investigator for severity and relatedness to study drug.
All clinical laboratory tests were performed by a central
laboratory. The investigator assessed local tolerability
and, with the patient, evaluated general tolerability at
every visit at dosing using a 5-point scale.
Statistical Analyses
Sample size was determined from results of a similarly
designed trial.28 A sample size of 93 patients/treatment
group allowed 90% power to demonstrate equivalence
between treatments in mean weekly hemoglobin level
and mean weekly epoetin dose/kg BW during the last 4
weeks of treatment in the maintenance phase, using 2
one-sided tests with a 2.5% signiﬁcance level. To account for an estimated 35% dropout rate, which reﬂects the estimated dropout from the beginning of the
titration phase and is similar to that used in a previous
study,28 288 patients (144/group) were planned for
enrollment into the titration phase.
The intent-to-treat (ITT) population, comprising all
patients randomized into the maintenance phase, was
used for the primary efﬁcacy analysis and analysis of
secondary efﬁcacy variables. Sensitivity analyses for
the primary variable were conducted on the perprotocol population: a subset of ITT patients who
had $4 weeks of study drug treatment during the
maintenance phase, no use of non–study-drug ESAs
1238
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during the last 4 weeks of treatment, and no
transfusions during the study.
Co-primary efﬁcacy endpoints, calculated as the leastsquares (LS) mean difference between treatments in mean
weekly hemoglobin level and mean weekly epoetin dose/
kg BW, were derived from hemoglobin level and dose
data collected during the last 4 weeks of treatment. Twosided 95% CIs for the 2 LS mean differences were
calculated using analysis of covariance (containing effect
for treatment and baseline value) and compared with
prespeciﬁed equivalence margins. The primary statistical
model for the co-primary endpoints used a hierarchical
test strategy: if equivalence between epoetin alfa-epbx
and epoetin alfa was concluded for mean hemoglobin
level (2-sided 95% CI within 0.5 g/dl equivalence
margin), the difference in mean weekly epoetin dose/kg
BW was tested; if equivalence was concluded for mean
weekly epoetin dose/kg BW (2-sided 95% CI within
45 U/kg per week equivalence margin), equivalence in
efﬁcacy between treatments was concluded. Because the
test on the mean weekly epoetin dose/kg BW calculation
was performed only if equivalence for hemoglobin level
was determined, no adjustment of alpha values was
required.
Mean weekly hemoglobin level and mean weekly
epoetin dose/kg BW over the 16-week maintenance
phase were summarized descriptively and analyzed by
t-test and the Mann–Whitney–Wilcoxon test, respectively. The proportion of patients with a weekly mean
hemoglobin level within the target range (9.0–11.0 g/
dl) at weeks 8 and 16 of the maintenance phase, and the
proportion of patients receiving blood transfusions,
were summarized with counts and percentages, and
analyzed by Fisher’s exact test.
All summaries of safety data were presented for the
safety population (all patients who received $1 dose of
study drug) by the ﬁrst treatment actually received
during the period of interest (titration or maintenance).
Safety data and demographic and baseline characteristics
were descriptively assessed. AEs were coded using
Medical Dictionary of Regulatory Activities version 14.1
terminology.29 Tolerability was summarized for each visit
as both continuous and discrete variables separately by
treatment phase (titration and maintenance). In addition,
the most severe tolerability a patient experienced was
summarized as both continuous and discrete variables.
RESULTS
Patient Populations, Disposition, and
Characteristics
Of the 556 patients screened, 320 across 68 US sites
were randomized into the titration phase (Figure 2). Of
these, 150 were previously on stable s.c. epoetin alfa
Kidney International Reports (2019) 4, 1235–1247
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and immediately re-randomized into the maintenance
phase, 166 were previously on stable i.v. epoetin alfa
and entered the titration phase on s.c. study drug
(safety population), and 4 were never treated. For the
safety population during the titration phase, mean
duration of study drug exposure for both treatment
groups was approximately 11 to 12 weeks. Seventy
patients discontinued study before the maintenance
phase, including 15 of 70 (21.4%) and 17 of 70 (24.3%)
in the epoetin alfa-epbx and epoetin alfa groups,
respectively, who did not meet criteria for entry into
the maintenance phase.
In total, 246 patients (ITT population) qualiﬁed for
the maintenance phase and were re-randomized to
receive epoetin alfa-epbx (n ¼ 124) or epoetin alfa
(n ¼ 122) (Figure 2). Of these, 1 of 124 (0.8%) randomized to epoetin alfa-epbx and 1 of 122 (0.8%)
randomized to epoetin alfa received no treatment with
study drug, 3 of 124 (2.4%) randomized to epoetin
alfa-epbx received actual treatment with epoetin alfa,
and 2 of 122 (1.6%) randomized to epoetin alfa
received actual treatment with epoetin alfa-epbx.
Three of 124 (2.4%) patients randomized to epoetin
alfa-epbx and 2 of 122 (1.6%) randomized to epoetin
alfa withdrew from the maintenance phase because of
AEs. The safety population in the maintenance phase
comprised 244 patients (epoetin alfa-epbx, n ¼ 122;
epoetin alfa, n ¼ 122).
For the safety population during the maintenance
phase, 14 of 122 (11.5%) patients in the epoetin alfaepbx group and 20 of 122 (16.4%) patients in the
epoetin alfa group switched to non–study-drug SoC
ESA for 1 or more of the following reasons (epoetin
alfa-epbx and epoetin alfa, respectively): SoC given in
error (n ¼ 2 and n ¼ 3), medical monitor decision (n ¼
0 and n ¼ 1), randomization delay (n ¼ 2 and n ¼ 0),
withdrawal by patient (n ¼ 1 and n ¼ 2), study drug
and SoC were both given in the same visit (n ¼ 2 and
n ¼ 0), AE/serious AE (SAE) (n ¼ 2 and n ¼ 8), SoC
given (n ¼ 2 and n ¼ 5), increased hemoglobin (n ¼
0 and n ¼ 1), sponsor decision (n ¼ 0 and n ¼ 1),
temperature excursion (n ¼ 3 and n ¼ 2), study drug
discontinued (n ¼ 0 and n ¼ 1), vacation (n ¼ 1 and n ¼
0), and other (n ¼ 1 and n ¼ 0). Mean duration of non–
study-drug SoC ESA exposure was 6.2 weeks and 4.7
weeks for patients in the epoetin alfa-epbx and epoetin
alfa groups, respectively.
Demographic and baseline clinical characteristics were
balanced between groups, and all patients had adequate
iron stores at maintenance-phase entry (Table 1). In the
epoetin alfa-epbx and epoetin alfa groups, respectively,
60.7% and 49.2% of patients received concomitant i.v.
iron supplementation at some time during the maintenance phase. Other common concomitant medications are
Kidney International Reports (2019) 4, 1235–1247
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summarized in Supplementary Table S1. One patient each
in the epoetin alfa-epbx and epoetin alfa groups tested
positive for anti-rhEPO antibodies at baseline, with titers
of 1:4 and 1:2, respectively.
Efﬁcacy
For the primary analysis conducted on the ITT population, the LS mean difference (95% CI) between
treatment groups in mean weekly hemoglobin levels
during the last 4 weeks of treatment was 0.04 g/dl
(0.17 to 0.24 g/dl) and in mean weekly epoetin
dose/kg BW was 2.34 U/kg per week (14.51 to
9.82 U/kg per week). The 95% CIs were contained
within the prespeciﬁed equivalence margins of 0.5 g/dl
(weekly hemoglobin) and 45 U/kg per week (weekly
epoetin dose/kg BW) (Table 2). Sensitivity analysis using
the per-protocol population demonstrated that the 95%
CIs for both co-primary endpoints were also contained
within the respective equivalence margins (Table 2).
Analysis of secondary efﬁcacy endpoints demonstrated that most epoetin alfa-epbx- and epoetin alfatreated patients maintained hemoglobin levels within
the range of 9.0 to 11.0 g/dl at week 16 of the treatment period; few patients in either group received
transfusions during the study (Table 2). Over the 16week maintenance phase, there was no difference
between groups in mean weekly hemoglobin (P ¼ 0.8)
or mean weekly epoetin dose/kg BW (P ¼ 0.7)
(Figure 3). In addition, the percentages of patients
requiring temporary (54.9%, epoetin alfa-epbx and
60.3%, epoetin alfa; P ¼ 0.6) or permanent (29.6%,
epoetin alfa-epbx and 20.5%, epoetin alfa; P ¼ 0.3)
dose changes of study drug were similar between
treatment groups.
Safety
For the safety population in the titration phase (epoetin
alfa-epbx, n ¼ 80; epoetin alfa, n ¼ 86), 59.6% of patients
in both groups reported at least 1 AE; the most common
AE was headache, which occurred with similar incidence
in both groups (Supplementary Table S2). AEs led to
study drug discontinuation in 4 (5.0%, epoetin alfa-epbx)
and 6 (7.0%, epoetin alfa) patients. Twelve (15.0%,
epoetin alfa-epbx) and 22 (25.6%, epoetin alfa) patients
reported SAEs. SAEs reported by 2 or more patients were
sepsis (n ¼ 2/group) and chronic obstructive pulmonary
disease (epoetin alfa-epbx, n ¼ 0; epoetin alfa, n ¼ 2). In
the epoetin alfa-epbx group, 4 (5.0%) patients discontinued study drug due to SAEs of cardiac arrest,
asthenia, colon cancer, or dyspnea. In the epoetin alfa
group, 6 (7.0%) patients discontinued study drug due to
SAEs of acute myocardial infarction, cardiac arrest, coronary artery disease, gastrointestinal angiodysplasia,
acute pyelonephritis, or decubitus ulcer. Three (3.8%)
1239
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Screened
(N = 556)
Screen failure
(n = 236)
Randomized to receive
epoetin alfa-epbx in titration phase
(n = 160)

Randomized to receive
epoetin alfa in titration phase
(n = 160)
Never treated
(n = 2)

Never treated
(n = 2)

Previously
on stable
s.c. epoetin alfa
(n = 78)

Previously on stable i.v.
epoetin alfa and treated
in titration phase with
s.c. epoetin alfa-epbx
(n = 80)

Previously on stable i.v.
epoetin alfa and treated
in titration phase with
s.c. epoetin alfa
(n = 86)

Discontinued study before maintenance phase
Othera
Did not meet criteria for maintenance phase
Adverse event
Withdrew consent
Lost to follow-up

Previously
on stable
s.c. epoetin alfa
(n = 72)

(n = 70)
(n = 25)
(n = 32)
(n = 8)
(n = 3)
(n = 2)

Met criteria for entry into maintenance phase
(n = 246)

Randomized to receive s.c.
epoetin alfa-epbx in maintenance phase
(n = 124)
Discontinued study
Other
Withdrew consent
Adverse event
Physician decision

(n = 18)
(n = 11)
(n = 3)
(n = 3)
(n = 1)

Completed study (n = 106)
Analyzed
Primary efficacy analysis
(ITT population): n = 124
Sensitivity analysis
(PP population): n = 86
Safety analysis
(safety population): n = 122

Randomized to receive s.c.
epoetin alfa in maintenance phase
(n = 122)
Discontinued study
Withdrew consent
Other
Adverse event
Physician decision
Lost to follow-up

(n = 17)
(n = 6)
(n = 5)
(n = 2)
(n = 2)
(n = 2)

Completed study (n = 105)
Analyzed
Primary efficacy analysis
(ITT population): n = 122
Sensitivity analysis
(PP population): n = 92
Safety analysis
(safety population): n = 122

Figure 2. Patient disposition. aOther reasons for study discontinuation before the maintenance phase included temperature excursion (n ¼ 7);
standard of care (n ¼ 6); sponsor (n ¼ 5); withdrew from dialysis (n ¼ 2); and did not meet criteria for maintenance phase, elevated hemoglobin,
started peritoneal dialysis, patient transferred, and patient went on vacation (n ¼ 1 each). ITT, intent-to-treat; PP, per-protocol; s.c.,
subcutaneous.
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Table 1. Demographic and baseline characteristics (safety
population)a

Table 2. Primary and secondary efﬁcacy endpoints
Endpoints

Characteristic

Epoetin alfa-epbx
n [ 122

Epoetin alfa
n [ 122

Primary efﬁcacy endpoints

Male, n (%)

63 (51.6)

55 (45.1)

Mean weekly hemoglobin level during last
4 weeks of treatment, g/dl

Age, yr, mean (SD)

57.36 (11.93)

56.50 (13.42)

Race, n (%)

Primary analysis (ITT population)

LS mean (SE)
Difference (95% CI)a

White

69 (56.6)

58 (47.5)

Black or African American

48 (39.3)

60 (49.2)

0

1 (0.8)

Asian

4 (3.3)

2 (1.6)

LS mean (SE)

American Indian or Alaska Native

1 (0.8)

1 (0.8)

Difference (95% CI)b

Native Hawaiian or other Paciﬁc Islander

Ethnicity, n (%)
Hispanic or Latino

34 (27.9)

31 (25.4)

Not Hispanic or Latino

88 (72.1)

91 (74.6)

Weight, kg, mean (SD)

85.04 (22.88)

86.59 (25.18)

Time from start of dialysis to randomization,
mo, mean (SD)

54.25 (52.44)

57.94 (41.52)

Hemoglobin level, g/dl, mean (SD)

10.36 (0.78)

Weekly epoetin dose by BW, U/kg per wk,
mean (SD)
Ferritin level, ng/ml, mean (SD)
TSAT, %, mean (SD)

93.53 (112.45)

10.28 (0.78)
b

85.91 (82.08)

Negative RIP
Positive RIP

Sensitivity analysis (per-protocol
population)

LS mean (SE)
Difference (95% CI)a

LS mean (SE)
Difference (95% CI)b

34.2 (14.50)

Secondary efﬁcacy endpoints (ITT
population)

108 (88.5)

104 (85.2)

Patients with mean weekly hemoglobin
within 9.0–11.0 g/dl at wk 16,c n/N (%)

1 (0.8)
17 (13.9)

Diabetes

56 (45.2)

41 (33.6)

Hypertension

43 (34.7)

58 (47.5)

Nephropathies

Primary cause of CKD, n (%)d

13 (10.5)

16 (13.1)

Congenital renal disease

5 (4.0)

3 (2.5)

Other

7 (5.6)

4 (3.3)

Anti-rhEPO, anti-recombinant human erythropoietin antibody; BW, body weight; CKD,
chronic kidney disease; ITT, intent-to-treat; RIP, radioimmunoprecipitation assay; TSAT,
transferrin saturation.
a
Analyses for all characteristics except primary cause of CKD were performed on the
safety population for the maintenance phase. The percentages for ‘race’ may not add
up to 100 because patients could select multiple races. Baseline was the last value
determined before first dose of study drug in the maintenance phase.
b
Mean (SD) weekly epoetin dose by BW (U/kg per wk) based on data for 121 patients
treated with epoetin alfa-epbx.
c
Baseline anti-rhEPO antibody samples were missing because of sample not being
drawn or sample handling. Missing samples were to be redrawn at the following visit,
but were not considered baseline values.
d
Analyses for primary cause of CKD were performed using the ITT population (epoetin
alfa-epbx, n ¼ 124; epoetin alfa, n ¼ 122).

patients receiving epoetin alfa-epbx and 1 (1.2%)
receiving epoetin alfa died during the titration
phase. The SAEs with fatal outcome in the epoetin
alfa-epbx (cardiac arrest, multifactorial functional
decline, and sepsis [n ¼ 1 each]) and epoetin alfa
(acute myocardial infarction) groups were considered
not related to study drug.
For the safety population in the maintenance phase
(n ¼ 122/group), approximately 70% of patients in
each group reported at least 1 AE, the most common
being nausea, which occurred with similar incidence in
both groups (Table 3). AEs led to study drug discontinuation in 4 (3.3%) patients in each group.
Twenty-three (18.9%, epoetin alfa-epbx) and 33
(27.0%, epoetin alfa) patients reported SAEs. The most
Kidney International Reports (2019) 4, 1235–1247

n ¼ 122

10.16 (0.07)

10.12 (0.07)

0.04 (0.17 to 0.24)

79.57 (4.36)

81.91 (4.37)

2.34 (14.51 to 9.82)

n ¼ 86

n ¼ 92

10.19 (0.08)

10.19 (0.08)

0.00 (0.23 to 0.23)

Mean weekly epoetin dose by BW during
last 4 weeks of treatment, U/kg per wk

927.7 (396.81)

1 (0.8)

n ¼ 124

Mean weekly hemoglobin level during last
4 weeks of treatment, g/dl

36.1 (13.40)

13 (10.7)

Missingc

Epoetin alfa

Mean weekly epoetin dose by BW during
last 4 weeks of treatment, U/kg per wk

990.9 (413.37)

Anti-rhEPO antibody status, n (%)

Epoetin alfa-epbx

73.85 (5.16)

83/104 (79.8)

P value
Patients who received a red blood cell
transfusion at any time during the 16-wk
maintenance phase, n/N (%)

P value

72.21 (4.96)

1.63 (12.48 to 15.75)

77/104 (74.0)

0.4108
5/124 (4.0)

5/122 (4.1)

>0.9999

BW, body weight; CI, conﬁdence interval; ITT, intent-to-treat; LS, least-squares; PP,
per-protocol.
a
The 95% CI for the LS mean of the difference (epoetin alfa-epbx – epoetin alfa) in mean
weekly hemoglobin had to reside within the equivalence margin of 0.5 g/dl for
equivalence to be concluded.
b
The 95% CI for the LS mean of the difference (epoetin alfa-epbx – epoetin alfa) in mean
weekly dose/kg BW had to reside within the equivalence margin of 45 U/kg per wk for
equivalence to be concluded.
c
Percentages are calculated using the number of observations at week 16 within a
treatment group as the denominator.

common SAEs reported by 2 or more patients (epoetin
alfa-epbx and epoetin alfa, respectively) were atrial
ﬁbrillation (n ¼ 1 and 2), cardiac arrest (n ¼ 2 and 0),
cardio-respiratory arrest (n ¼ 0 and 2), impaired gastric
emptying (n ¼ 1 and 2), noncardiac chest pain (n ¼ 2
and 1), cellulitis (n ¼ 2 and 0), osteomyelitis (n ¼ 2 and
0), pneumonia (n ¼ 3 and 2), hyperkalemia (n ¼ 2 and
2), hypoglycemia (n ¼ 0 and 4), and mental impairment
(n ¼ 1 and 2). In the epoetin alfa-epbx group, 4 (3.3%)
patients discontinued study drug due to SAEs of
gastrointestinal hemorrhage, multiple fractures, tibia
fracture, or respiratory failure. In the epoetin alfa
group, 3 (2.5%) patients discontinued study drug due
to SAEs of atrial ﬁbrillation, hypoglycemia, or pulmonary edema.
Three (2.5%) patients receiving epoetin alfa-epbx
and 2 (1.6%) receiving epoetin alfa died during the
maintenance phase. The SAEs with fatal outcome in the
epoetin alfa-epbx group (cardiac arrest, gastrointestinal
bleed, and azotemia [n ¼ 1 each]) were considered not
related to study drug. The 2 deaths in the epoetin alfa
1241

CLINICAL RESEARCH

a

S Fishbane et al.: Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa

11.5

Hemoglobin level (g/dl)

11.0

10.5

10.0

9.5

9.0

8.5
0

1

2

3

4

5

6

7

8
Week

9

Epoetin alfa-epbx

10

11

12

13

14

15

16

12

13

14

15

16

Epoetin alfa

b 220
200
180
160
Dose (U/kg/week)

140
120
100
80
60
40
20
0
–20
0

1

2

3

4

5

6

7

8
Week

9

10

11

Figure 3. Mean (SD) weekly hemoglobin level (g/dl) (a) and mean (SD) weekly epoetin dose by body weight (BW; U/kg/week) (b) during the
maintenance phase. Analyses were performed on the intent-to-treat (ITT) population. Over the 16-week maintenance phase, there was no
difference between groups in mean weekly hemoglobin (P ¼ 0.8) or mean weekly epoetin dose/kg BW (P ¼ 0.7).
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Table 3. Treatment-emergent adverse events occurring in $5% of
patients in either treatment group during the maintenance phase
Preferred term
Any treatment-emergent AE, n (%)

Epoetin alfa-epbx
n [ 122

Epoetin alfa
n [ 122

85 (69.7)

86 (70.5)

Nausea

10 (8.2)

8 (6.6)

Pyrexia

8 (6.6)

4 (3.3)

Fall

8 (6.6)

3 (2.5)

Dizziness

3 (2.5)

9 (7.4)

Injection-site pain

3 (2.5)

8 (6.6)

AE, adverse event.

group (arrhythmia and aortic stenosis [n ¼ 1 each])
were considered probably not related to study drug.
Patients receiving epoetin alfa were more likely to
experience a hemoglobin excursion <8.0 or >12.0 g/dl
at some point during the maintenance phase than were
patients receiving epoetin alfa-epbx; excursions >13.0
or >14.0 g/dl were relatively infrequent (Table 4).
Clinical laboratories, vital signs, and postdialysis BW
were stable in both groups throughout the duration of
the study. During the maintenance phase, blood pressure was similar between the 2 treatment groups over
time (Figure 4). Mean changes from baseline to week 16
during the maintenance phase (epoetin alfa-epbx and
epoetin alfa, respectively) for plasma ferritin (11.5
and 42.3 ng/ml) and transferrin saturation (1.8% and
0.6%) were clinically unremarkable. Throughout the
study, iron stores remained adequate in both groups
and were able to support erythropoiesis stimulated by
epoetin. There were no notable changes in electrocardiogram ﬁndings in either group.
Using current validated methods, 5 patients (epoetin
alfa-epbx, n ¼ 2; epoetin alfa, n ¼ 3) were conﬁrmed
anti-rhEPO antibody-positive, 2 of whom (n ¼ 1 each/
group) tested positive at baseline before the ﬁrst dose
of study drug in the maintenance phase, and 3 of whom
(epoetin alfa-epbx, n ¼ 1; epoetin alfa, n ¼ 2) developed anti-rhEPO antibodies while on study treatment.
Table 4. Hemoglobin excursions and investigator-rated local tolerability during the maintenance phase
Variable

Epoetin alfa-epbx
n [ 122

Epoetin alfa
n [ 122

Hemoglobin excursions, n (%)
<8.0 g/dl

5 (4.1)

11 (9.0)

>12.0 g/dl

12 (9.8)

24 (19.7)

>13.0 g/dl

3 (2.5)

4 (3.3)

>14.0 g/dl

1 (0.8)

1 (0.8)

1. Excellent tolerability

82 (67.2)

66 (54.1)

2. Good tolerability

30 (24.6)

37 (30.3)

3. Mild intolerability

5 (4.1)

11 (9.0)

4. Moderate intolerability

2 (1.6)

4 (3.3)

0

3 (2.5)

Most severe local tolerability rating,a n (%)

5. Severe intolerability
a

The most severe response per week is summarized for each patient.

Kidney International Reports (2019) 4, 1235–1247
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The patient in the epoetin alfa-epbx group who was
conﬁrmed anti-rhEPO antibody-positive at baseline
had a titer of 1:4; titers for the remaining 4 patients
were between <1:2 and 1:2. All 5 patients tested
negative for neutralizing antibodies and were clinically
stable.
Both treatments were well-tolerated; the most severe
local tolerability rating during the maintenance phase
was reported by the investigator as “good” or “excellent” in 112 (91.8%) and 103 (84.4%) patients in the
epoetin alfa-epbx and epoetin alfa groups, respectively
(Table 4). Three (2.5%, epoetin alfa-epbx) and 8 (6.6%,
epoetin alfa) patients experienced injection-site pain, 1
(0.8%, epoetin alfa-epbx) experienced injection-site
erythema, and 1 (0.8%, epoetin alfa) experienced
injection-site swelling.
DISCUSSION
Regulatory guidance for biosimilar development provides analytical, nonclinical, and clinical testing requirements to assess biosimilarity between a proposed
biosimilar and the licensed biologic.10,11 As part of an
overall program to demonstrate biosimilarity of epoetin
alfa-epbx to the reference product, epoetin alfa, this
study evaluated the equivalence of the 2 s.c. treatments
in patients with ESKD and anemia who were on hemodialysis. The study met its prespeciﬁed co-primary
efﬁcacy endpoints by demonstrating equivalence between epoetin alfa-epbx and epoetin alfa in mean
weekly hemoglobin levels and mean weekly epoetin
dose/kg BW. Sensitivity and secondary efﬁcacy analyses support the results of the primary analysis.
The co-primary endpoints were selected because
both are clinically relevant and sensitive to evaluate
change. The equivalence margin (0.5 g/dl) for evaluating LS mean difference in mean weekly hemoglobin
levels was selected because it was used to demonstrate
equivalence between biosimilar and reference epoetin
products in previous studies,28,30 and because even
well-titrated patients with renal anemia who receive
stable doses of epoetin experience intraindividual
ﬂuctuations (1 g/dl) in hemoglobin levels.31,32 The
equivalence margin (45 U/kg per wk) for evaluating
LS mean difference in mean weekly epoetin dose/kg
BW was selected based on key principles of a no-effect
dose, true-effect dose, guidelines for dose modiﬁcation
in the epoetin alfa US prescribing information,26,27 and
because it was used to demonstrate equivalence in
previous studies.28,30
As noted, s.c. administration was selected for this
study because it is generally considered to be the route
most likely to elicit an immune reaction,23,24 and was
therefore considered a more sensitive assessment for
1243
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Figure 4. Box plots of systolic (a) and diastolic (b) blood pressures over time. The box represents the 25th and 75th percentiles and the tails
represent the minimum and maximum observed values; the median is indicated by the horizontal line, and the mean by the asterisk.

detecting potential differences in immunogenicity between the biosimilar and the reference product, should
they exist. Most patients on hemodialysis receive
epoetin i.v.; however, s.c. administration is used in
some US hemodialysis units, and in patients on peritoneal dialysis or with nondialysis CKD.33 Patients on
1244

hemodialysis with ESKD are the most erythropoietindeﬁcient population across the licensed indications
for epoetin alfa, and therefore the most likely to
reveal potential differences in efﬁcacy between
products. Patients with ESKD are also less immunocompromised and have higher risk of pure red cell
Kidney International Reports (2019) 4, 1235–1247
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aplasia than other patients for whom epoetin alfa is
indicated (e.g., patients with cancer receiving myelosuppressive chemotherapy). Therefore, the current
study was designed to evaluate similarity between
epoetin alfa-epbx and epoetin alfa using the route of
administration and study population deemed most
sensitive for identifying a difference in immunogenicity between the 2 products across the conditions
of use. Current ﬁndings provide important information for the patient populations in which s.c.
administration is used, and contributed to the totality of evidence and scientiﬁc justiﬁcation for
extrapolation of data that supported a demonstration
of biosimilarity and licensure of epoetin alfa-epbx in
all indications of the reference product.
Epoetin alfa-epbx and epoetin alfa had similar safety
proﬁles. All AEs (including SAEs) observed in this
study were consistent with those expected for an ESKD
population receiving epoetin, generally similar between the 2 treatment groups, and concordant with the
type and incidence of AEs described for epoetin
alfa.26,27 Patients with CKD have an increased all-cause
mortality, which increases as kidney function decreases.34–36 Cardiovascular disease is the leading cause
of death in patients with CKD34,35; thus, 5 of the 9
deaths in this study resulting from cardiovascular
causes are not unexpected. Subcutaneous administration was well-tolerated by patients in both groups;
local tolerability ratings were similar and injection-site
AEs were infrequent.
Protein therapeutic drugs have the potential to elicit
an immune response,37 and neutralizing antibodies to
epoetin can result in pure red cell aplasia or severe
anemia,26,27,38 particularly when administered s.c.39
Three patients (epoetin alfa-epbx, n ¼ 1; epoetin alfa,
n ¼ 2) developed anti-rhEPO antibodies while on study
treatment; however, no patient in either treatment
group had neutralizing antibodies or reported events of
pure red cell aplasia or hypersensitivity consistent with
immunogenic response to epoetin.
This comparative clinical trial demonstrated equivalence in efﬁcacy and similar safety between s.c.administered epoetin alfa-epbx and epoetin alfa. One
limitation of the study was that investigators were
permitted to switch patients from study drug to non–
study-drug SoC ESA and retain them in the trial.
However, it is unlikely that SoC exposure inﬂuenced
the efﬁcacy results because the primary analysis of coprimary efﬁcacy endpoints was corroborated by a
sensitivity analysis using the per-protocol population,
which excluded patients receiving non–study-drug
SoC ESA during the last 4 weeks of treatment. The
16-week length of the study also limited the duration
of evaluation of epoetin alfa-epbx treatment.
Kidney International Reports (2019) 4, 1235–1247

The strengths of this trial include its double-blind
nature, use of the ITT population for primary efﬁcacy
analyses, individualized study drug dosing per SoC
epoetin dosing guidelines, rigor associated with coprimary endpoints required to demonstrate equivalence in efﬁcacy, and robustness added by the sensitivity analysis and secondary endpoints. Additional
safety and persistence of efﬁcacy data are under evaluation in the 48-week, open-label extension trial.
The introduction of biosimilars to European markets
has been associated with price reductions and increased
patient access across product classes.40 A 2017 report
estimated a price reduction of 31% and an increase in
uptake of 66% across the epoetin drug class (i.e., for
reference and biosimilar products) in several European
countries following the introduction of epoetin biosimilars.40 In the United States, treatment for patients
with ESKD is covered by Medicare, which reimburses
dialysis providers for the cost of services, laboratory
testing, and medications related to kidney disease,
including ESAs (e.g., epoetin), at a bundled rate.41,42
However, Medicare reimbursement under the bundled
payment system may not completely cover the costs of
treatment, which could negatively impact dialysis facilities (e.g., limit their operation or services, lead to
closure), thereby affecting the quality of patient care or
access to treatment.41,42 Availability of lower-cost
epoetin biosimilars could generate savings for dialysis
providers and maintain patient access to high-quality
care. Results of this comparative efﬁcacy and safety
trial demonstrating equivalence of epoetin alfa-epbx to
epoetin alfa via s.c. administration support the opportunity to provide patients with additional treatment
options that offer the same beneﬁts as epoetin therapy
but at a potential lower overall cost.
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